Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
89bio, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for liver and cardio-metabolic diseases. Its lead product, pegozafermin, targets metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). With significant market potential driven by rising obesity rates, 89bio aims to address unmet medical needs through ongoing clinical trials and has received Breakthrough Therapy designation from the FDA, enhancing its growth prospects.
This description was generated via AI from an annual report. Updated about 1 year ago.